ARRHYTHMOGENIC CARDIOMYOPATHY: CONTEMPORARY CONCEPTS IN DIAGNOSIS, RISK STRATIFICATION, AND MANAGEMENT
Keywords:
arrhythmogenic cardiomyopathy; arrhythmogenic right ventricular cardiomyopathy; sudden cardiac death; ventricular arrhythmias; desmosomal mutations; cardiac MRI; risk stratification; implantable cardioverter-defibrillator.Abstract
Arrhythmogenic cardiomyopathy (ACM) is a genetically determined myocardial disease characterized by progressive fibrofatty replacement of the ventricular myocardium, ventricular arrhythmias, heart failure, and an increased risk of sudden cardiac death, particularly in young individuals and athletes. Contemporary understanding of ACM has evolved from a predominantly right ventricular disorder to a broader disease spectrum that includes biventricular and left-dominant phenotypes. Advances in molecular genetics, electrocardiography, cardiac magnetic resonance imaging, and genetic testing have significantly improved diagnostic accuracy and disease characterization. Despite these advances, ACM remains diagnostically and therapeutically challenging because of its heterogeneous clinical presentation and variable disease progression. Current management strategies focus on early diagnosis, risk stratification, prevention of malignant ventricular arrhythmias, lifestyle modification, pharmacological therapy, catheter ablation, and implantable cardioverter-defibrillator implantation. This review summarizes contemporary concepts in the pathophysiology, diagnosis, risk stratification, and evidence-based management of ACM, highlighting recent developments that are shaping modern clinical practice.
References
1.Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. European Heart Journal. 2010;31(7):806–814.
2.Corrado D, Link MS, Calkins H. Arrhythmogenic right ventricular cardiomyopathy. New England Journal of Medicine. 2017;376:61–72.
3.Towbin JA, McKenna WJ, Abrams DJ, et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm. 2019;16(11):e301–e372.
4.Corrado D, Basso C, Judge DP. Arrhythmogenic cardiomyopathy. Circulation Research. 2017;121(7):784–802.
5.Calkins H, Corrado D, Marcus F. Risk stratification in arrhythmogenic right ventricular cardiomyopathy. Circulation. 2017;136(21):2068–2082.
6.Towbin JA. Inherited cardiomyopathies. Circulation Journal. 2014;130:1767–1780.
7.James CA, et al. 2022 ESC Guidelines for ventricular arrhythmias and sudden cardiac death prevention. European Heart Journal. 2022.
8.Basso C, Thiene G. The pathophysiology of arrhythmogenic cardiomyopathy. Cardiovascular Pathology. 2015;24(4):173–179.




United Kingdom
Germany
France
Uzbekistan
Türkiye
Kazakhstan
Kyrgyzstan
Turkmenistan
Azerbaijan
India
Republic of Korea
Japan
United States of America
Kosovo
Italy
Spain
Poland
Netherlands
Belgium
Sweden
Norway
Finland
Denmark
Switzerland
Austria
Czech Republic
Hungary
Romania
Bulgaria
Greece
Portugal